Group 1 - The company has received the clinical trial approval notice for the nasal congestion granules from the National Medical Products Administration [1] - The nasal congestion granules are indicated for the treatment of acute sinusitis and have shown good efficacy and safety in clinical applications [1][2] - The market for nasal medication is significant, with 26% of the adult population in China suffering from nasal inflammation or sinusitis, and the market demand for nasal medication is expected to grow [2] Group 2 - The sales revenue for nasal medication (traditional Chinese medicine) is projected to be 2.757 billion yuan in 2023 and 3.061 billion yuan in 2024, with the nasal congestion granules expected to generate sales of 409 million yuan in 2023 and 475 million yuan in 2024 [2] - There are several traditional Chinese medicine products approved for the treatment of acute sinusitis, including nasal congestion granules, with one approval number for the nasal congestion granules [3] - The company must complete clinical trials and submit a marketing authorization application to the National Medical Products Administration before the product can be marketed [4]

Core Viewpoint - Jianmin Group has received the clinical trial approval notice for its nasal medication, indicating progress in its product development pipeline [2] Company Summary - Jianmin Group announced on August 14 that it has obtained the clinical trial approval from the National Medical Products Administration for its nasal medication, Nasal Congestion Relief Granules [2]

Group 1 - The core point of the article is that Jianmin Group has received the clinical trial approval notice for its nasal medication, indicating a significant development in its product pipeline [2] - Jianmin Group's revenue composition for the year 2024 is as follows: pharmaceutical manufacturing accounts for 49.83%, pharmaceutical commerce for 49.56%, and other businesses for 0.6% [2]

证券简称：健民集团 证券代码：600976 公告编号：2025-031 健民药业集团股份有限公司 关于获得《药物临床试验批准通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局签发的鼻渊通窍颗粒《药物临床试验批准通知书》。按照《上海证券交易所 上市公司自律监管指引第3号——行业信息披露》的相关要求，现将有关情况公告 如下： | 药品名称 | 鼻渊通窍颗粒 | 申请人 | 健民药业集团股份有限公司 | | --- | --- | --- | --- | | 注册分类 | 中药4类 | 剂型 | 颗粒剂 | | 通知书编号 | 2025LP02040 | 受理号 | CYZL2500001 | | 适应症 | 急性鼻窦炎 | | | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，鼻渊通窍颗粒临床试 | | | | | 验申请符合药品注册的有关要求，同意本品开展用于急性鼻窦炎的临床 | | | | | 试验。 | | | 二、药 ...

Core Viewpoint - Jianmin Group (600976.SH) has received the Clinical Trial Approval Notice for the nasal medication "Biyuan Tongqiao Granules" from the National Medical Products Administration, indicating a significant step in the development of this traditional Chinese medicine [1] Group 1 - The product "Biyuan Tongqiao Granules" is a traditional Chinese medicine that has already been marketed [1] - The primary function of the granules is to dispel wind and clear heat, as well as to promote lung function and open nasal passages [1] - The medication is indicated for acute nasal inflammation (acute sinusitis) associated with external pathogens affecting the lungs, with symptoms including pressure pain in the forehead or cheekbones, nasal congestion, and other related symptoms [1]

Core Viewpoint - The company, Jianmin Group, has received approval from the National Medical Products Administration for clinical trials of its nasal medication, indicating a significant step in the development of a treatment for acute sinusitis [1] Company Summary - Jianmin Group (stock code: 600976) announced on August 14 that it has obtained the "Drug Clinical Trial Approval Notice" for its product, Nasal Congestion Relief Granules [1] - The approved indication for this medication is acute sinusitis, which suggests potential market opportunities in addressing this common health issue [1]

Core Viewpoint - The company will hold an investor briefing on August 21, 2025, to discuss its 2025 semi-annual report and address common investor concerns [2][3][4]. Group 1: Meeting Details - The investor briefing is scheduled for August 21, 2025, from 15:00 to 16:00 [4]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [4][5]. - Investors can submit questions from August 14 to August 20, 2025, through the Roadshow Center website or via the company's email [2][5]. Group 2: Participants - Key participants in the meeting will include the company's Chairman, independent directors, President, CFO, and Secretary of the Board [4]. Group 3: Participation Method - Investors can join the briefing online on the specified date and time, and the company will respond to questions in real-time [5]. - Investors are encouraged to pre-submit questions to facilitate the discussion during the meeting [5]. Group 4: Contact Information - For inquiries, investors can contact the company representatives via phone or email [6][7].

Core Viewpoint - Jianmin Group (600976) announced plans to hold a semi-annual performance briefing on August 21, 2025, from 15:00 to 16:00 [1] Summary by Relevant Sections - Company Announcement - Jianmin Group will conduct a semi-annual performance briefing in 2025 [1]

Core Viewpoint - The company will hold a half-year performance briefing on August 21, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in interactive communication [2][3]. Group 1: Meeting Details - The performance briefing is scheduled for August 21, 2025, from 15:00 to 16:00 [2][3]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [2][3]. - Investors can submit questions from August 14 to August 20, 2025, through the Shanghai Stock Exchange Roadshow Center website or via the company's email [2][3]. Group 2: Participants - Key participants in the meeting will include the company's Chairman, independent directors, President, CFO, and Secretary of the Board [2][3]. Group 3: Investor Participation - Investors can participate online during the meeting and will receive timely responses to their questions [3]. - The company encourages investors to actively engage in the performance briefing and will provide access to the meeting's main content afterward [3].

证券代码：600976 证券简称：健民集团 公告编号：2025-030 健民药业集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 8 月 21 日(星期四)下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 健民药业集团股份有限公司（以下简称"公司"）将于 2025 年 8 月 20 日发 布公司《2025 年半年度报告》，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 8 月 21 日下午 15:00-16:00 举行 2025 年半年度业绩说明会，就投资者普遍关心的问题进行交流。 一、说明会类型 投资者可于 2025 年 8 月 14 日(星期四)至 8 月 20 日(星期三)16:00 ...